Views & Analysis How can the UK improve in clinical research? A biotech persp... The UK is a great place for early-stage research – but NHS red tape and market access remain major barriers.
Views & Analysis Immigration is the Brexit bogeyman, and it’s hurting pharma ... The UK pharma and biotech sectors are warning that a Hard Brexit will hit patients, R&D and the country's ability to attract the best global talent.
Views & Analysis European biotech round-up: Ablynx’s big break and more European biotech: a mixture of encouraging clinical trials and new funding lift the sector.
News Immunocore hires Lilly's Hotchkiss as chief commercial offic... UK biotech leading in the nascent field of TCR immunotherapy has appointed Andrew Hotchkiss as its new Chief Commercial Officer.
Views & Analysis UK biotech round-up: Autolus joins CAR-T race, Horizon’s new... Three small, innovative firms demonstrate the diversity and promise of the UK bioscience sector.
Views & Analysis Europe has untapped medical innovation – but needs high spee... The head of Johnson & Johnson (J&J) Innovation in Europe says the region is ripe for more life sciences investment, but warns that the UK, its biotech leader, could miss out withou
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
